TrialsgrambetaRCTs are beautiful
ESC Congress 2026Presentado dom, 30 ago · 11:55 CESTHot Line 7Todos los ensayos Hot Line →

NOTION-4

2026

The Nordic Aortic Valve Intervention Trial 4 — Prospective Study on the Impact of Different Anti-thrombotic Therapies on Subclinical Leaflet Thickening and Its Temporal Dynamics in Transcatheter Bioprosthetic Aortic Valves

In 352 patients after TAVI without an indication for anticoagulation, 3 months of a DOAC, then antiplatelet therapy did not reduce leaflet thrombosis on CT at 1 year compared with antiplatelet therapy alone.

Resultado

number of patients with at least one bioprosthetic aortic valve leaflet with HALT on 4-dimensional cardiac CT at 1 year after TAVI
Diferencia absoluta
3,9 puntos
Estimación del efecto

risk difference-3,9IC del 95% -14,4 to 6,6 · P = 0,54

La diferencia absoluta se deriva de las tasas de eventos.

También se informa: At 3 months, on DOAC, HALT 12.1% vs 31.8%. All-cause death, stroke or major/life-threatening bleeding at 12 months 8.2% vs 2.3% (risk difference 5.9%, 95% CI 1.2 to 10.6).

Publicación original
Subtema
TAVR antithrombotics
Diseño
investigator-initiated, randomised, open-label, superiority trial at two Danish centres (Rigshospitalet Copenhagen, Aarhus University Hospital); early 3-month DOAC then single antiplatelet vs lifelong single antiplatelet therapy; 4D-CT and clinical assessment at 3 months, 1 year and 5 years
Relevancia
Importante: uno de varios pilares.
Fuente
Jørgensen TH, Larsen AF, Jensen JM, et al. Short-Term Anticoagulant Therapy and Subclinical Leaflet Thickening in Transcatheter Aortic Valves: The NOTION-4 Trial. J Am Coll Cardiol. 2026 Aug 30 (online first). doi:10.1016/j.jacc.2026.08.023doi 10.1016/j.jacc.2026.08.023

Discusión y crítica

Three months of anticoagulation clears the leaflets while it is being taken and the effect is gone nine months after stopping: the thrombus comes back, so a short course buys nothing durable. Against that stands harm: death, stroke or major bleeding in 8.8% versus 2.3%, a difference the trial was not powered for but which points the same way as GALILEO. Two Danish centres and 352 patients, an imaging endpoint, and the honest reading is the presenters' own: this regimen does not belong in patients without another indication for anticoagulation.